Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatments & Surgery
Share your love
ESCRS 2024 Exclusive Insights: iNovation Day in Focus
The European Society of Cataract and Refractive Surgeons (ESCRS) is gearing up for an innovative event with its iNovation® Day in Barcelona, Spain, on Friday 6 September 2024 at the Fira Barcelona Gran Via. Scheduled to be held prior to…
Bimekizumab Reduces Uveitis Incidence in axSpA Patients
The study led by Matthew A. Brown, Genomics England, London, United Kingdom, and Martin Rudwaleit, Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany. Patients with axial spondyloarthritis (axSpA) treated with bimekizumab exhibited a markedly lower incidence of uveitis compared to those receiving…
Nerve Regrowth Breakthrough for Blindness
Researchers at the University of Connecticut have uncovered promising findings that may pave the way for treating a common cause of blindness. The study, published in the September issue of Experimental Neurology, demonstrates how injured optic nerves in mice can…
U.S. Glaucoma Prevalence and Risk Factors Study
A new study titled “Prevalence of Glaucoma Among US Adults in 2022”, published in JAMA Ophthalmology, has revealed updated statistics on the prevalence of glaucoma in the United States. The research shows that approximately 4.22 million U.S. adults (1.62% of…
Cataract Surgery Lowers Risk of Falls and Injuries
Cataract surgery is well-known for restoring vision, but a new study reveals it may also play a vital role in reducing life-threatening injuries. Research presented at the annual meeting of the American Academy of Ophthalmology in Chicago suggests that older…
Long-Term Antiviral Therapy for Ocular Shingles
A new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine suggests that taking an antiviral medication for a year can help prevent vision loss caused by…
SLT Beats Medications in Glaucoma – AAO 2024
A recent retrospective analysis of the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial data demonstrated that selective laser trabeculoplasty (SLT) as a first-line treatment significantly outperforms glaucoma medications in reducing the rate of visual field (VF) loss. This study,…
Fluorescent Gel Boosts Cataract Surgery Safety
Cataracts, a condition that clouds the eye’s lens and impairs vision, are a near-universal experience with age. To improve safety in cataract surgery, scientists at Johns Hopkins have engineered a novel color-changing hydrogel that can help surgeons avoid complications in…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…